Standard Biotools Inc (LAB) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Standard Biotools Inc   (NASDAQ: LAB)


Standard Biotools Inc's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Standard Biotools Inc's ROI in the third quarter of 2026?
Standard Biotools Inc achieved a return on average invested assets (ROI) of 24.07 % in its third quarter of 2026, this is above LAB's average return on investment of -22.49%.
Standard Biotools Inc invested over the 12 months ending in its third quarter of 2026 $553 million

ROI has improved compared to 16.5% in the second quarter of 2026, due to net income growth.

Within the Healthcare sector 65 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Sep 30 2026 quarter, so far to 454, from total ROI ranking in the second quarter of 2026 at 459.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Investment Change TTM 12.79 % -1.49 % -12.13 % -20.23 % -2.74 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 584 570 597 459 432
Return On Investment (TTM) 24.07 % 16.5 % 16.07 % -15.99 % -26.17 %
LAB's Overall Ranking # 454 # 459 # 2691 # 2309 #
Seq. Investment Change TTM 7.42 % 5.73 % 3.93 % -4.44 % -6.19 %
Seq. Net Income Change TTM 56.73 % 8.57 % - - -
Net Income (TTM) in Millions 133 85 78 -75 -128

LAB Company Profile >> Back to LAB Roi Comparisons >> See Annual LAB Return On Investment



Return On Investment LAB's Ranking
Within: No.
Industry # 3
Sector # 66
Overall # 454

Return On Investment Statistics
High Average Low
16.38 %
-22.49 %
-56.07 %
(Jun 30 2026)   (Jun 30 2022)







Financial Statements
Standard Biotools Inc's III. Quarter Investments $ 584 Millions LAB's Balance sheet
Standard Biotools Inc's III. Quarter Income $ 13 Millions Quarterly LAB's Income Statement
LAB's Income by Division See LAB's Income by Division


LAB Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 459 546 214 347 226
Y / Y Investment Growth -15.92 % 155.66 % -38.38 % 53.72 % -16.58 %
Net Income in Millions -75 -139 -75 -190 -59
Y / Y Net Income Growth - - - - -
Annual Return On Investment -16.3 % -25.42 % -34.93 % -54.8 % -26.25 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Laboratory Analytical Instruments Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
LAB's Roi Ratio versus Laboratory Analytical Instruments Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for LAB's Competitors
Subscribers only: Roi for Standard Biotools Inc's Suppliers
Subscribers only: Return On Investment for LAB's Customers

Other Ratios
LAB's Roa LAB's Inventory Turnover Ratio LAB's Growth Rates LAB's Dividend Statistics
LAB's Profitability Ratios LAB's Asset Turnover Ratio LAB's Dividend Growth
LAB's Roe LAB's Valuation Ratios LAB's Financial Strength Ratios LAB's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector ROI
Alnylam Pharmaceuticals Inc   63.14 %
Idexx Laboratories Inc  52.51 %
Aurinia Pharmaceuticals Inc   45.04 %
Nurix Therapeutics Inc   44.12 %
Medpace Holdings Inc   41.14 %
Rallybio Corporation  36.04 %
Eli Lilly And Company  32.00 %
Caredx Inc   30.65 %
Zevra Therapeutics Inc   29.88 %
Acadia Pharmaceuticals Inc   26.89 %
Standard Biotools Inc   23.91 %
Iradimed Corporation  22.98 %
Corcept Therapeutics Inc  22.08 %
Resmed Inc   21.10 %
Alector Inc   20.83 %
Chemed Corporation  20.46 %
Halozyme Therapeutics Inc   19.64 %
Pro dex Inc   19.11 %
Dexcom Inc   18.92 %
Illumina Inc   18.74 %
Denali Therapeutics Inc   17.88 %
West Pharmaceutical Services Inc   17.65 %
Healthcare Services Group Inc   17.18 %
Neurocrine Biosciences Inc   16.94 %
Krystal Biotech Inc   16.91 %
Vertex Pharmaceuticals Inc  16.63 %
Intuitive Surgical Inc   16.30 %
Hca Healthcare Inc   15.54 %
Kiniksa Pharmaceuticals International Plc  15.45 %
Carlisle Companies Incorporated  13.64 %

Date modified: 2026-11-04T15:19:00+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.